Pharmaceutical composition derived from eucommia ulmoides and use of pharmaceutical composition
A technology of composition and medicine, which is applied in the field of pharmaceutical composition derived from Eucommia, can solve the problems of large dosage and long time, and achieve the effect of obvious curative effect, better and more significant effect, and great clinical development value
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0021] Example 1 Effect of pharmaceutical composition on osteoporosis caused by ovariectomy (OVX) in rats
[0022] Female SD rats, about 200g, were randomly divided into groups (12 in each group). The castrated rats were operated as follows, anesthetized by ether inhalation, and under strict aseptic operation, a median incision was made on the posterior side of the lumbar spine, and the paravertebral muscles were bluntly separated. tissue, cut the peritoneum, and enter the abdominal cavity. After complete removal of both ovaries, penicillin was sprinkled, the skin was sutured, and the wound was disinfected. The operation of the sham operation group was the same as above, only a little fat tissue around the ovary was removed, and the ovaries were not removed. After the model was established, the rats were given intragastric administration. The dosage of each administration group was 30 mg / kg per day for 6 weeks. , the component weight ratio of each administration group is as f...
Embodiment 2
[0039] Example 2 Effect of pharmaceutical composition on rat osteoporosis caused by retinoic acid
[0040] Get female SD rats, about 200g, and randomly divide them into groups (12 in each group). Rats in the model group and each administration group are given 80 mg / kg of retinoic acid by intragastric administration every day for 14 days. After successful modeling, start Rats were administered intragastrically, and the dosage of each administration group was 30 mg / kg per day for 4 weeks. The weight ratio of the components of each administration group was the same as that in Example 1.
[0041] The specific results are as follows:
[0042] group
[0043] Dosing group 3
[0044] ▲▲P<0.01 compared with the sham operation group, **P<0.01 compared with the model group
Embodiment 3
[0045] Example 3 Effect of pharmaceutical composition on mouse embryonic osteoblast MC3T3-E1 proliferation and mineralization
[0046] Take the MC3T3-E1 cells grown in the logarithmic phase, and dilute them with MEM complete medium to 2×10 4 cells / ml, 1ml per well was spread into a 24-well plate, cultivated in an incubator for 3 days, removed the complete medium, added serum-free medium containing the pharmaceutical composition to a final drug concentration of 30 μg / L, and cultivated for 48 hours. The model group was without Serum medium, the cell proliferation was measured by MTT method, and the cell mineralization function (bone nodule formation rate) was measured by Alizarin red method. The specific results are as follows:
[0047] group
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com